The U.S. Food and Drug Administration's Mini‐Sentinel program: status and direction
暂无分享,去创建一个
Richard Platt | Sengwee Toh | Sebastian Schneeweiss | Sean Hennessy | Lesley H Curtis | Judith A Racoosin | Jennifer C Nelson | Elizabeth Chrischilles | Mark G Weiner | S. Schneeweiss | R. Platt | J. Racoosin | J. Nelson | L. Curtis | M. Robb | Jeffrey S. Brown | S. Hennessy | M. Weiner | R. Carnahan | S. Toh | E. Chrischilles | Jeffrey S Brown | Melissa A. Robb | Ryan M Carnahan | Melissa Robb
[1] R. Platt,et al. Developing the Sentinel System--a national resource for evidence development. , 2011, The New England journal of medicine.
[2] E. Perencevich,et al. A systematic review of validated methods for identifying infection related to blood products, tissue grafts, or organ transplants using administrative data , 2012, Pharmacoepidemiology and drug safety.
[3] R. Carnahan,et al. A systematic review of validated methods for identifying transfusion‐related ABO incompatibility reactions using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[4] M. Reynolds,et al. A systematic review of validated methods for identifying erythema multiforme major/minor/not otherwise specified, Stevens–Johnson Syndrome, or toxic epidermal necrolysis using administrative and claims data , 2012, Pharmacoepidemiology and Drug Safety.
[5] R. Carnahan,et al. A systematic review of validated methods for identifying transfusion‐related sepsis using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[6] David Madigan,et al. When should case‐only designs be used for safety monitoring of medical products? , 2012, Pharmacoepidemiology and drug safety.
[7] J. Pearl. Invited commentary: understanding bias amplification. , 2011, American journal of epidemiology.
[8] R. Carnahan,et al. A systematic review of validated methods for identifying lymphoma using administrative data , 2012, Pharmacoepidemiology and drug safety.
[9] M. Granner,et al. A systematic review of validated methods for identifying seizures, convulsions, or epilepsy using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[10] L. Tamariz,et al. A systematic review of validated methods for identifying ventricular arrhythmias using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[11] Thomas P. Gross,et al. The US Food and Drug Administration's Sentinel Initiative: Expanding the horizons of medical product safety , 2012, Pharmacoepidemiology and drug safety.
[12] L. Tamariz,et al. A systematic review of validated methods for identifying venous thromboembolism using administrative and claims data , 2012, Pharmacoepidemiology and Drug Safety.
[13] Andrea J Cook,et al. Statistical approaches to group sequential monitoring of postmarket safety surveillance data: current state of the art for use in the Mini‐Sentinel pilot , 2012, Pharmacoepidemiology and drug safety.
[14] Jerry H. Gurwitz,et al. Mini-Sentinel Systematic Evaluation of Health Outcome of Interest Definitions for Studies Using Administrative and Claims Data: Heart Failure , 2012 .
[15] Jerry H. Gurwitz,et al. A systematic review of validated methods for identifying heart failure using administrative data , 2012, Pharmacoepidemiology and drug safety.
[16] Michael Nguyen,et al. The Food and Drug Administration's Post‐Licensure Rapid Immunization Safety Monitoring program: strengthening the federal vaccine safety enterprise , 2012, Pharmacoepidemiology and drug safety.
[17] Malcolm Maclure,et al. Design considerations in an active medical product safety monitoring system , 2012, Pharmacoepidemiology and drug safety.
[18] Andrea J Cook,et al. Challenges in the design and analysis of sequentially monitored postmarket safety surveillance evaluations using electronic observational health care data , 2012, Pharmacoepidemiology and drug safety.
[19] Brian Sauer,et al. Guidelines for good database selection and use in pharmacoepidemiology research , 2012, Pharmacoepidemiology and drug safety.
[20] R. Carnahan,et al. Mini‐Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative and claims data: methods and lessons learned , 2012, Pharmacoepidemiology and drug safety.
[21] M. Reynolds,et al. A systematic review of validated methods for identifying anaphylaxis, including anaphylactic shock and angioneurotic edema, using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[22] Philip Rotella,et al. A systematic review of validated methods for identifying acute respiratory failure using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[23] Marsha A Raebel,et al. Design considerations, architecture, and use of the Mini‐Sentinel distributed data system , 2012, Pharmacoepidemiology and drug safety.
[24] Mark Olfson,et al. A systematic review of validated methods for identifying suicide or suicidal ideation using administrative or claims data , 2012, Pharmacoepidemiology and drug safety.
[25] Philip Rotella,et al. A systematic review of validated methods for identifying hypersensitivity reactions other than anaphylaxis (fever, rash, and lymphadenopathy), using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[26] Sengwee Toh,et al. A protocol for active surveillance of acute myocardial infarction in association with the use of a new antidiabetic pharmaceutical agent , 2012, Pharmacoepidemiology and drug safety.
[27] Sengwee Toh,et al. Design for validation of acute myocardial infarction cases in Mini‐Sentinel , 2012, Pharmacoepidemiology and drug safety.
[28] James Floyd,et al. A systematic review of validated methods for identifying atrial fibrillation using administrative data , 2012, Pharmacoepidemiology and drug safety.
[29] Barbara Evans,et al. A policy framework for public health uses of electronic health data , 2012, Pharmacoepidemiology and drug safety.
[30] Sebastian Schneeweiss,et al. Using high‐dimensional propensity scores to automate confounding control in a distributed medical product safety surveillance system , 2012, Pharmacoepidemiology and drug safety.
[31] M. Reynolds,et al. A systematic review of validated methods for identifying pulmonary fibrosis and interstitial lung disease using administrative and claims data , 2012, Pharmacoepidemiology and drug safety.
[32] Richard Platt,et al. The organizational structure and governing principles of the Food and Drug Administration's Mini‐Sentinel pilot program , 2012, Pharmacoepidemiology and drug safety.
[33] Mohit Bhandari,et al. A systematic review of validated methods for identifying orthopedic implant removal and revision using administrative data , 2012, Pharmacoepidemiology and drug safety.
[34] R. Carnahan,et al. Mini‐Sentinel's systematic reviews of validated methods for identifying health outcomes using administrative data: summary of findings and suggestions for future research , 2012, Pharmacoepidemiology and drug safety.
[35] J. Gurwitz,et al. A systematic review of validated methods for identifying cerebrovascular accident or transient ischemic attack using administrative data , 2012, Pharmacoepidemiology and drug safety.
[36] R. Platt,et al. The new Sentinel Network--improving the evidence of medical-product safety. , 2009, The New England journal of medicine.
[37] J. Myers,et al. Effects of adjusting for instrumental variables on bias and precision of effect estimates. , 2011, American journal of epidemiology.
[38] R. Carnahan,et al. A systematic review of validated methods for identifying pancreatitis using administrative data , 2012, Pharmacoepidemiology and drug safety.
[39] Mark Olfson,et al. A systematic review of validated methods for identifying depression using administrative data , 2012, Pharmacoepidemiology and drug safety.